Study suggests tumour microenvironments could predict cancer progression
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Apr 12, 2024 | News | 0
NSCLC is the most common type of lung cancer and is responsible for up to 85% of all cases
Read Moreby Jen Brogan | Feb 1, 2024 | News | 0
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read Moreby Jen Brogan | Jan 12, 2024 | News | 0
If successful, the new test could see routine screening introduced in the NHS
Read Moreby Jen Brogan | Dec 7, 2023 | News | 0
The disease is one of the leading causes of cancer deaths in the UK
Read Moreby Jen Brogan | Dec 1, 2023 | News | 0
Every year, around 55,000 women in the UK are diagnosed with the condition
Read Moreby Jen Brogan | Nov 21, 2023 | News | 0
SMPaeds2 aims to advance precision medicines for children with relapsed cancer
Read Moreby Jen Brogan | Nov 3, 2023 | News | 0
Over 63,000 cancer cases were diagnosed between one and five years after referral
Read Moreby Jen Brogan | Sep 21, 2023 | News | 0
The investment will support research into cancer treatments and diagnosis
Read Moreby John Pinching | Dec 13, 2022 | News | 0
DETERMINE trial aims to discover if current treatments could benefit patients with other cancer types
Read Moreby Lucy Parsons | Sep 22, 2021 | News | 0
Cancer Research UK has partnered with the University of Edinburgh’s ‘venture builder incubator’
Read Moreby Lucy Parsons | Jul 15, 2021 | News | 0
Investment raised by its spinouts more than doubled in the last year, the charity has reported
Read Moreby Lucy Parsons | Jun 23, 2021 | News | 0
Partnership will advance the early clinical development of CAR-T cell engager candidate ALETA-001
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479